Clover Biopharmaceuticals

About Clover Biopharmaceuticals

Clover Biopharmaceuticals is a global, commercial-stage biotechnology company focused on developing vaccines for infectious diseases, as well as therapies for cancer and autoimmune diseases. Founded in June 2007 by Dr. Peng Liang, the company leverages its proprietary Trimer-Tag© technology platform. This platform enables the creation of novel, covalently-trimerized fusion proteins, targeting disease pathways that are dependent on trimerization, such as the entry of enveloped RNA viruses into host cells.

The company's history is marked by significant milestones, including its response to the COVID-19 pandemic. Clover developed SCB-2019 (CpG 1018/Alum), a protein-based subunit vaccine. This vaccine candidate demonstrated 100% efficacy against severe COVID-19 in global Phase II/III trials and received Emergency Use Authorization in China in December 2022. The commercial launch in China began in February 2023. The company’s primary clients are governments and healthcare organizations, with vaccine distribution facilitated through partnerships, including an agreement with the COVAX Facility for global supply. Revenue is generated from product sales and collaborations.

Dr. Peng Liang, the founder, Chairman, and Chief Scientific Officer, is the inventor of the Trimer-Tag© technology. His background includes a postdoc at Harvard Medical School and serving as an Associate Professor at Vanderbilt University, with extensive research published in peer-reviewed journals. The company's leadership team also includes Joshua Liang as CEO. Clover Biopharmaceuticals held its Initial Public Offering (IPO) on the Hong Kong Stock Exchange in November 2021, raising approximately HK$2 billion (US$260 million). The company's pipeline extends beyond COVID-19, with a focus on a respiratory vaccine franchise that includes candidates for Respiratory Syncytial Virus (RSV), seasonal influenza, and pneumococcal disease.